235 related articles for article (PubMed ID: 20130242)
21. Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity.
Hotblack A; Seshadri S; Zhang L; Hamrang-Yousefi S; Chakraverty R; Escors D; Bennett CL
Mol Ther; 2017 Feb; 25(2):504-511. PubMed ID: 28153097
[TBL] [Abstract][Full Text] [Related]
22. Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?
Speiser DE; Cerottini JC; Romero P
Cancer Immun; 2002 Oct; 2():14. PubMed ID: 12747759
[TBL] [Abstract][Full Text] [Related]
23. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
24. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
25. Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity.
Xiang J; Munegowda MA; Deng Y
Cancer Gene Ther; 2009 May; 16(5):430-8. PubMed ID: 19096444
[TBL] [Abstract][Full Text] [Related]
26. Prospects and challenges of building a cancer vaccine targeting telomerase.
Vonderheide RH
Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
[TBL] [Abstract][Full Text] [Related]
27. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.
Chapatte L; Colombetti S; Cerottini JC; Lévy F
Cancer Res; 2006 Jan; 66(2):1155-60. PubMed ID: 16424053
[TBL] [Abstract][Full Text] [Related]
28. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector.
Colombetti S; Lévy F; Chapatte L
Blood; 2009 Jun; 113(26):6629-37. PubMed ID: 19383968
[TBL] [Abstract][Full Text] [Related]
29. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P; Köksal H; Maggadottir SM; Winge-Main A; Pollmann S; Menard M; Myhre MR; Mælandsmo GM; Flørenes VA; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Mol Ther; 2021 Mar; 29(3):1199-1213. PubMed ID: 33212301
[TBL] [Abstract][Full Text] [Related]
30. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
[TBL] [Abstract][Full Text] [Related]
31. Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.
Wang Y; Zhang J; Wu Y; Ding ZY; Luo XM; Liu J; Zhong WN; Deng GH; Xia XY; Deng YT; Wei YQ; Jiang Y
Sci Rep; 2015 Jun; 5():11275. PubMed ID: 26085010
[TBL] [Abstract][Full Text] [Related]
32. Telomerase based anticancer immunotherapy and vaccines approaches.
Kailashiya C; Sharma HB; Kailashiya J
Vaccine; 2017 Oct; 35(43):5768-5775. PubMed ID: 28893481
[TBL] [Abstract][Full Text] [Related]
33. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
34. In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.
Chen L; Liang GP; Tang XD; Chen T; Cai YG; Fang DC; Yu ST; Luo YH; Yang SM
Biochem Biophys Res Commun; 2006 Dec; 351(4):927-34. PubMed ID: 17097054
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors.
Frolkis M; Fischer MB; Wang Z; Lebkowski JS; Chiu CP; Majumdar AS
Cancer Gene Ther; 2003 Mar; 10(3):239-49. PubMed ID: 12637945
[TBL] [Abstract][Full Text] [Related]
36. Telomerase in cancer immunotherapy.
Liu JP; Chen W; Schwarer AP; Li H
Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
[TBL] [Abstract][Full Text] [Related]
37. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
38. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
39. Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.
Miyazaki Y; Fujiwara H; Asai H; Ochi F; Ochi T; Azuma T; Ishida T; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2013 Jun; 121(24):4894-901. PubMed ID: 23641014
[TBL] [Abstract][Full Text] [Related]
40. Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo.
Ciré S; Da Rocha S; Yao R; Fisson S; Buchholz CJ; Collins MK; Galy A
PLoS One; 2014; 9(7):e101644. PubMed ID: 25058148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
